Dexcom to Add Ambulatory Glucose Profile (AGP) to Dexcom CLARITY

EDINBURGH, Scotland, September 11, 2017 /PRNewswire/ --

DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that it incorporated Ambulatory Glucose Profile (AGP) into its Dexcom CLARITY software for Europe. A web-based software, Dexcom CLARITY provides access to clinically relevant metrics and reports for data analyses and diabetes management planning.

     (Logo: http://mma.prnewswire.com/media/553571/Dexcom_Logo.jpg )
The Ambulatory Glucose Profile report, known as captūrAGP^®, was developed by the International Diabetes Center (IDC), with input from endocrinologists and clinicians who are experts in data management and interpretation.^[1],[2] AGP includes a summary of patient glucose data in three parts:

(1) statistical summary, (2) visual display, and (3) daily views. These components create a common platform for patients and clinicians to view glucose patterns and trends.

"Dexcom is pleased to partner with the IDC in implementing a standard report across all platforms - allowing physicians and health care professionals to compare information in a consistent format," said Kevin Sayer, President and Chief Executive Officer, Dexcom. "As the industry leader in continuous glucose monitoring, it is important that we align with industry recommendations and clinical societies to provide the tools and information needed to help clinicians improve clinic work flow while managing their patients' diabetes with glucose data and reporting."

Dexcom will be featuring the new updates to Dexcom CLARITY, including AGP, at the 53^rd Annual Meeting of the European Association for the Study of Diabetes (EASD). Dexcom CLARITY experts will be available to demo the software in our booth L03.

"I hope that utilising the AGP to standardise CGM metrics and the glucose profile display will help clinicians and patients together to formulate a personalised action plan to optimise glucose control," says Richard Bergenstal, MD, Endocrinologist and Executive Director of the International Diabetes Center, St Louis Park, MN.

"AGP reports have been used for several years by physicians," explained George Grunberger, MD, FACP, FACE, Chairman of the Grunberger Diabetes Institute in Bloomfield Hills, MI and immediate past-president of AACE (2015-2016), "and presents the most relevant statistical and graphical information that would allow clinicians to quickly assess the glucose control of a patient and make meaningful clinical decisions. By having a wider adoption of this report by medical device companies, it allows the information to be agnostic to the manufacturer. AGP can become the EKG report of diabetology - where there is one standard glucose report that all clinicians can interpret."

About DexCom, Inc.
Founded in 1999, DexCom, Inc. has corporate offices in San Diego, California, EMEA headquarters in Edinburgh, Scotland and patients in 39 countries around the world. At Dexcom, we are transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class-while empowering our community to take control of diabetes. For more information on Dexcom CGM, visit http://www.dexcom.com/global

To view multimedia assets, please visit: http://www.dexcom.com/media

References
1. Bergenstal RM, Ahmann A, Bailey T, et al. Recommendations for standardising glucose reporting and analysis to optimise clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15:198-211.

2. Mullen DM. (2017, February 1). AGP [Online]. Available at: http://www.AGPreport.org